Table 3.
CSF ELISA testing of patients (DCM) and controls (TAAA).
| CSF ELISA testing | DCM | TAAA | P* | ηp2 |
|---|---|---|---|---|
| M [SD] | M[SD] | |||
| Angiogenic mediators | N = 24 | N = 23 | ||
| Angiopoietin 2 (pg/ml) | 267.1 [81.9] | 408.6 [177.1] | < .001 | .22 |
| VEGF C (pg/ml) | 152.2 [96.1] | 222.4 [140.3] | .04 | .09 |
| VEGF A (pg/ml) | 15.3 [8.5] | 15.4 [13.0] | .98 | .00 |
| Inflammatory mediators | N = 21 | N = 27 | ||
| IL1 beta (pg/ml) | 1.7 [4.6] | 1.2 [1.0] | .60 | .01 |
| IL 8 (pg/ml) | 72.6 [74.8] | 291.1 [721.8] | .14 | .05 |
| Rantes (pg/ml) | 3.2 [10.0] | 2.8 [3.3] | .88 | .00 |
CSF cerebrospinal fluid, DCM degenerative cervical myelopathy, pg/ml picogram per milliliter, M mean, SD standard deviation, TAAA thoracic-abdominal aortic aneurysm.
*p values reflect the univariate post-hoc between group tests revealed by the MANOVAs; ηp2 = partial eta squared effect size.
Bold values indicate significance level of p < .05.